Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mark Fleming Laboratory, |
RCV001526369 | SCV001736692 | pathogenic | Sideroblastic anemia 2 | 2021-06-01 | criteria provided, single submitter | research | |
Gene |
RCV001751785 | SCV001986378 | uncertain significance | not provided | 2019-04-09 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 29499877, 21393332) |
Labcorp Genetics |
RCV001751785 | SCV003525211 | uncertain significance | not provided | 2024-05-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 228 of the SLC25A38 protein (p.Gly228Val). This variant is present in population databases (rs755205622, gnomAD 0.007%). This missense change has been observed in individuals with congenital sideroblastic anemia (PMID: 29499877). ClinVar contains an entry for this variant (Variation ID: 1172495). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC25A38 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dr. |
RCV001526369 | SCV005061404 | pathogenic | Sideroblastic anemia 2 | no assertion criteria provided | clinical testing |